1. Home
  2. OPAD vs NEUP Comparison

OPAD vs NEUP Comparison

Compare OPAD & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OPAD

Offerpad Solutions Inc.

HOLD

Current Price

$4.45

Market Cap

24.5M

Sector

Finance

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.95

Market Cap

23.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPAD
NEUP
Founded
2015
1996
Country
United States
United States
Employees
140
8
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
24.5M
23.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OPAD
NEUP
Price
$4.45
$3.95
Analyst Decision
Buy
Strong Buy
Analyst Count
4
2
Target Price
$1.83
$21.00
AVG Volume (30 Days)
56.7K
90.8K
Earning Date
04-30-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$32.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$3.19
52 Week High
$6.35
$21.31

Technical Indicators

Market Signals
Indicator
OPAD
NEUP
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
OPAD
NEUP

About OPAD Offerpad Solutions Inc.

Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: